Michael Cloonan sold $3.6M of SION
President & CEO at Sionna Therapeutics, Inc.. 99,800 shares at an average of $36.26, traded Oct 21, 2025, filed Oct 22, 2025.
Score components
- +25RoleCEO
- +25Trade size$3.6M at market
- +5Share of holdings soldSold 18% of holdings
- +15Cluster3 insiders selling within 14 days
- -15Exercise and sellShares came from an option exercise in the same filing
- -2010b5-1 planPre-scheduled under a 10b5-1 plan
What happened after comparable sells
Same side and tier, against the S&P 500, at 1, 3 and 6 months. Shown to Pro users; the whole table is on the backtest page.
This signal so far: 1m +12.2%, 3m +4.9%, 6m +11.1%.
Price around the trade, and since
From a quarter before the trade to today. The arrow is the trade, the circle the day the filing reached EDGAR, which is the first day anyone outside could act; the dotted line is the S&P 500 rebased to that day's close.
Daily candles, adjusted for splits and dividends. Green arrows are insider buys, red are sells, sized by value; the dashed line is the close on the filing day, the dotted line SPY rebased to it.Charts by TradingView Lightweight Charts™
Rows in this filing
Every transaction in Form 4 0001704336-25-000008, as filed. Open on EDGAR
| Date | Transaction | Shares | Price | Value | Holdings after | Filed |
|---|---|---|---|---|---|---|
| Oct 21, 2025 | MOption exercise Common Stock10b5-1 | +13,324 | $6.11 | $81k | 560,667 | Oct 22, 2025 |
| Oct 21, 2025 | SOpen-market sale Common Stock10b5-1 | -13,324 | $34.44 | $459k | 547,343 | Oct 22, 2025 |
| Oct 21, 2025 | MOption exercise Common Stock10b5-1 | +30,049 | $6.11 | $184k | 577,392 | Oct 22, 2025 |
| Oct 21, 2025 | SOpen-market sale Common Stock10b5-1 | -30,049 | $35.63 | $1.1M | 547,343 | Oct 22, 2025 |
| Oct 21, 2025 | MOption exercise Common Stock10b5-1 | +22,895 | $6.11 | $140k | 570,238 | Oct 22, 2025 |
| Oct 21, 2025 | SOpen-market sale Common Stock10b5-1 | -22,895 | $36.60 | $838k | 547,343 | Oct 22, 2025 |
| Oct 21, 2025 | MOption exercise Common Stock10b5-1 | +33,532 | $6.11 | $205k | 580,875 | Oct 22, 2025 |
| Oct 21, 2025 | SOpen-market sale Common Stock10b5-1 | -33,532 | $37.31 | $1.3M | 547,343 | Oct 22, 2025 |
| Oct 21, 2025 | MOption exercise Non-Qualified Stock Option (right to buy)derivative10b5-1 | -13,324 | $0.00 | $0 | 139,618 | Oct 22, 2025 |
| Oct 21, 2025 | MOption exercise Non-Qualified Stock Option (right to buy)derivative10b5-1 | -30,049 | $0.00 | $0 | 109,569 | Oct 22, 2025 |
| Oct 21, 2025 | MOption exercise Non-Qualified Stock Option (right to buy)derivative10b5-1 | -22,895 | $0.00 | $0 | 86,674 | Oct 22, 2025 |
| Oct 21, 2025 | MOption exercise Non-Qualified Stock Option (right to buy)derivative10b5-1 | -33,532 | $0.00 | $0 | 53,142 | Oct 22, 2025 |
Related signals
Other insiders at Sionna Therapeutics, Inc. and this insider’s other filings.
| Score | Company | Insider | Value | Holdings | Filed |
|---|---|---|---|---|---|
| 50Moderate | SIONsell Sionna Therapeutics, Inc. | Ra Capital Management, L.p. director, owner | $22M 3,448,811 shares | -50% | |
| 35Weak | Sionna Therapeutics, Inc. | Orbimed Advisors LLC director | $3.9M 85,918 shares | -3% | |
| 35Weak | Sionna Therapeutics, Inc. | Peter A. Thompson director | $3.9M 85,918 shares | -3% | |
| 32Weak | Sionna Therapeutics, Inc. | Jennifer Fitzpatrick Chief Legal Officer | $447k 10,250 shares | -100% | |
| 35Weak | Sionna Therapeutics, Inc. | Orbimed Advisors LLC director | $5.3M 115,844 shares | -4% | |
| 35Weak | Sionna Therapeutics, Inc. | Peter A. Thompson director | $5.3M 115,844 shares | -4% | |
| 3Weak | Sionna Therapeutics, Inc. | Orbimed Advisors LLC director | $4,493 101 shares | -0% | |
| 3Weak | Sionna Therapeutics, Inc. | Peter A. Thompson director | $4,493 101 shares | -0% | |
| 28Weak | Sionna Therapeutics, Inc. | Orbimed Advisors LLC director | $13M 292,952 shares | -10% | |
| 28Weak | Sionna Therapeutics, Inc. | Peter A. Thompson director | $13M 292,952 shares | -10% |
Not investment advice. Scores and forward returns are decision support built from public SEC filings and past prices; they describe what happened after comparable filings, not what will happen after this one. Do your own research and size your risk.